HBIO vs. AXTI, RELL, TRVG, ZFOX, LTRX, REKR, GWH, SATL, UEIC, and RDCM
Should you be buying Harvard Bioscience stock or one of its competitors? The main competitors of Harvard Bioscience include AXT (AXTI), Richardson Electronics (RELL), trivago (TRVG), ZeroFox (ZFOX), Lantronix (LTRX), Rekor Systems (REKR), ESS Tech (GWH), Satellogic (SATL), Universal Electronics (UEIC), and RADCOM (RDCM). These companies are all part of the "computer and technology" sector.
AXT (NASDAQ:AXTI) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap computer and technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, community ranking, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.
Harvard Bioscience has higher revenue and earnings than AXT. Harvard Bioscience is trading at a lower price-to-earnings ratio than AXT, indicating that it is currently the more affordable of the two stocks.
AXT presently has a consensus target price of $5.38, suggesting a potential upside of 63.87%. Given Harvard Bioscience's higher probable upside, research analysts clearly believe AXT is more favorable than Harvard Bioscience.
Harvard Bioscience has a net margin of -8.18% compared to Harvard Bioscience's net margin of -21.01%. AXT's return on equity of 0.26% beat Harvard Bioscience's return on equity.
AXT received 76 more outperform votes than Harvard Bioscience when rated by MarketBeat users. However, 72.02% of users gave Harvard Bioscience an outperform vote while only 64.63% of users gave AXT an outperform vote.
AXT has a beta of 2.28, suggesting that its stock price is 128% more volatile than the S&P 500. Comparatively, Harvard Bioscience has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.
49.5% of AXT shares are owned by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are owned by institutional investors. 8.4% of AXT shares are owned by insiders. Comparatively, 9.0% of Harvard Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, AXT had 7 more articles in the media than Harvard Bioscience. MarketBeat recorded 9 mentions for AXT and 2 mentions for Harvard Bioscience. AXT's average media sentiment score of 0.00 beat Harvard Bioscience's score of 0.00 indicating that Harvard Bioscience is being referred to more favorably in the news media.
Summary
Harvard Bioscience beats AXT on 10 of the 17 factors compared between the two stocks.
Get Harvard Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for HBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Harvard Bioscience Competitors List
Related Companies and Tools
